Literature DB >> 7919561

Sertraline-phenelzine drug interaction: a serotonin syndrome reaction.

M A Graber1, T B Hoehns, P J Perry.   

Abstract

OBJECTIVE: To report a serious drug interaction possibly occurring with the monoamine oxidase inhibitor phenelzine and the selective serotonin reuptake inhibitor sertraline. CASE
SUMMARY: A 61-year-old woman with treatment-refractory major depressive disorder was being treated unsuccessfully with lithium, phenelzine, thioridazine, and doxepin. Sertaline 100 mg/d was added to the patient's therapy. Within three hours of ingesting the first dose, the patient experienced a dramatic increase in her temperature, pulse, and respirations along with labile blood pressure, and symptoms of rigidity, diaphoresis, shivering, and decreased sensorium. The patient was transported to the emergency room and treated with diazepam 10 mg iv, followed by midazolam 10 mg iv for control of rigidity. She was also intubated. The patient then experienced precipitous falls in her blood pressure and respiratory rate. Ice packs combined with a cooling blanket and dantrolene 80 mg iv were administered to control fever and rigidity, respectively. She had an initial working diagnosis of neuroleptic malignant syndrome, which was later changed to serotonin syndrome. Dantrolene was continued for 72 hours at which time the patient was extubated and transferred to a psychiatric unit.
CONCLUSIONS: Selective serotonin reuptake inhibitor antidepressants should not be combined with monoamine oxidase inhibitor antidepressants because of the risk of serotonin syndrome.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7919561     DOI: 10.1177/106002809402800610

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  5 in total

Review 1.  Selective serotonin reuptake inhibitors in older patients. A tolerability perspective.

Authors:  U Skerritt; R Evans; S A Montgomery
Journal:  Drugs Aging       Date:  1997-03       Impact factor: 3.923

Review 2.  The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders.

Authors:  G MacQueen; L Born; M Steiner
Journal:  CNS Drug Rev       Date:  2001

Review 3.  The serotonin syndrome. Implicated drugs, pathophysiology and management.

Authors:  K A Sporer
Journal:  Drug Saf       Date:  1995-08       Impact factor: 5.606

4.  Serotonin syndrome due to venlafaxine overdose.

Authors:  R J Daniels
Journal:  J Accid Emerg Med       Date:  1998-09

Review 5.  Dantrolene: mechanisms of neuroprotection and possible clinical applications in the neurointensive care unit.

Authors:  Susanne Muehlschlegel; John R Sims
Journal:  Neurocrit Care       Date:  2008-08-12       Impact factor: 3.532

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.